01 agosto 2014

AMERICAN HEART JOURNAL. Is there a role for diastolic function assessment in era of delayed enhancement cardiac magnetic resonance imaging?

João L. Cavalcante, MD, Thomas H. Marwick, MD, PhD, MPH, Rory Hachamovitch, MD, MSc, Zoran B. Popovic, MD, PhD, Nael Aldweib, MD, Randall C. Starling, MD, MPH, Milind Y. Desai, MD, Scott D. Flamm, MD, MBA, Deborah H. Kwon, MD

Background: Cardiac magnetic resonance (CMR) identifies important prognostic variables in ischemic cardiomyopathy (ICM) patients such as left ventricular (LV) volumes, LV ejection fraction (LVEF), peri-infarct zone, and myocardial scar burden (MSB). It is unknown whether Doppler-based diastolic dysfunction (DDF) retains its prognostic value in ICM patients, in the context of current imaging, medical, and device therapies.

01 diciembre 2014

AMERICAN HEART JOURNAL. Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention

Elena Guerra, MD, Gjin Ndrepepa, MD, Stefanie Schulz, MD, Robert Byrne, MD, Petra Hoppmann, MD, Sebastian Kufner, MD, Tareq Ibrahim, MD, Tomohisa Tada, MD, Heribert Schunkert, MD, Karl-Ludwig Laugwitz, MD, Adnan Kastrati, MD

Background: Inhospital stent thrombosis (ST) and cerebrovascular accidents (CVA) are rare but serious adverse events after percutaneous coronary intervention (PCI). The association of ST or CVA with long-term outcome after PCI remains poorly investigated.

01 diciembre 2014

AMERICAN HEART JOURNAL. Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement

Laurent Feldman, MD, PhD, Florence Tubach, MD, PhD, Jean-Michel Juliard, MD, Dominique Himbert, MD, Grégory Ducrocq, MD, Emmanuel Sorbets, MD, Konstantinos Triantafyllou, MD, Arthur Kerner, MD, Hélène Abergel, Msc, Marie-Geneviève Huisse, MD, Phd, Ronan Roussel, MD, PhD, Marina Esposito-Farèse, PhD, Philippe Gabriel Steg, MD, Nadine Ajzenberg, MD, PhD

Background: Previous studies, which compared the prevalence of high on-clopidogrel platelet reactivity (HCPR) in type 2 diabetes mellitus (T2DM) versus non-T2DM and obese versus nonobese patients provided conflicting results.

01 diciembre 2014

AMERICAN HEART JOURNAL. Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program

Marco Valgimigli, MD, PhD, The MATRIX investigators

Background: Transradial intervention (TRI) and bivalirudin infusion compared with transfemoral coronary intervention or unfractionated heparin plus glycoprotein IIb/IIIa inhibitors decrease bleeding complications in patients with acute coronary syndromes (ACS). Although bleeding is thought to be associated with worse outcomes, it remains unclear whether TRI and bivalirudin both independently lower ischemic or combined ischemic and bleeding complications in ACS patients undergoing contemporary invasive management.

01 noviembre 2014

AMERICAN HEART JOURNAL. Transesophageal echocardiography in patients with cryptogenic ischemic stroke: A systematic review

Emer R. McGrath, MB, PhD, Jeremy S. Paikin, MDe, Bahareh Motlagh, MD, Omid Salehian, MD, Moira K. Kapral, MD, Martin J. O´Donnell, MB, PhD

Background: The clinical utility of routine transesophageal echocardiography (TEE) for patients with unexplained ischemic stroke is controversial. We performed a systematic review to determine the frequency of detection of new cardiac findings in patients with cryptogenic ischemic stroke (IS) undergoing transesophageal echocardiography (TEE).

01 noviembre 2014

AMERICAN HEART JOURNAL. Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations

Raban V. Jeger, MD, Matthias E. Pfisterer, MDi, Rikke Sørensen, MD, Stefanie von Felten, PhD, Hannes Alber, MD, Piero O. Bonetti, MD, Franz Eberli, MD, Paul Erne, MD, Giovanni Pedrazzini, MD, Hans Rickli, MD, Søren Galatius, MD, Christoph A. Kaiser, MD for the BASKET and BASKET-PROVE investigators

Background: The tradeoff between stent thrombosis (ST) and major bleeding (MB) of 12- versus 6-month dual antiplatelet therapy (DAPT) after coronary stent implantation has not been clearly defined.

01 noviembre 2014

AMERICAN HEART JOURNAL. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study

Guillaume Cayla, MD, PhDs, Thomas Cuisset, MD, PhD, Johanne Silvain, MD, PhDs, Patrick Henry, MD, PhD, Florence Leclercq, MD, PhD, Didier Carrié, MD, PhD, Christophe Saint Etienne, MD, Loic Belle, MD, PhD, Grégoire Rangé, MD, Christophe Pouillot, MD, Olivier Varenne, MD, PhD, Eric Van Belle, MD, PhD, Ziad Boueri, MD, Pascal Motreff, MD, PhD, Simon Elhadad, MD, Nicolas Delarche, MD, Rami El Mahmoud, MD, Eric Vicaut, MD, PhD, Jean-Philippe Collet, MD, PhDs, Gilles Montalescot, MD, PhDs for the ANTARCTIC investigators

Background: Elderly patients are at high risk for both ischemic and bleeding events. Platelet monitoring offers the opportunity to individualized antiplatelet therapy to optimize the therapeutic risk/benefit ratio.

01 noviembre 2014

AMERICAN HEART JOURNAL. Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous β-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention

Vincent Roolvink, MD, Saman Rasoul, MD, PhD, Jan Paul Ottervanger, MD, PhD, Jan-Henk E. Dambrink, MD, PhD, Erik Lipsic, MD, PhD, Iwan C.C. van der Horst, MD, PhD, Bart de Smet, MD, PhD, Elvin Kedhi, MD, PhD, A.T. Marcel Gosselink, MD, PhD, Jan J. Piek, MD, PhD, Vicente Sanchez-Brunete, MD, Borja Ibanez, MD, PhD, Valentin Fuster, MD, PhD, Arnoud W.J. van’t Hof, MD, PhD, The EARLY-BAMI investigators

Background: β-Blockers have a class 1a recommendation in the treatment of patients with ST-elevation myocardial infarctions (STEMIs), as they are associated with a reduced mortality, recurrent myocardial infarction, life-threatening arrhythmias, and with prevention of unfavorable left ventricular remodeling. Whether early administration before primary percutaneous coronary intervention (PCI) of intravenous β-blockers reduces the infarct size in the current era is unknown.

01 noviembre 2014

AMERICAN HEART JOURNAL. APPOSITION V: STENTYS coronary stent system clinical trial in subjects with ST-segment elevation myocardial infarction—Rationale and design

Maik J. Grundeken, MDl, Huangling Lu, MDl, Roxana Mehran, MD, Donald E. Cutlip, MD, Martin B. Leon, MD, Alan Yeung, MD, Karel T. Koch, MD, PhD, Gilles Montalescot, MD, PhD, Robert-Jan van Geuns, MD, PhD, René Spaargaren, MD, Maurice Buchbinder, MD

Background: Primary percutaneous coronary intervention (PCI) has considerably improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) when compared with thrombolytic therapy. Prognosis after primary PCI might be further improved by decreasing stent-related complications such as stent thrombosis. The STENTYS self-apposing stent has been shown to be superior compared with balloon-expandable stents with regard to stent apposition. The current prospective randomized trial was designed to evaluate whether the superior stent apposition of the STENTYS stent results in clinical outcomes that are at least noninferior to a conventional balloon-expandable stent.

01 noviembre 2014

AMERICAN HEART JOURNAL. How can we optimize the processes of care for acute coronary syndromes to improve outcomes?

Lars Wallentin, MD, PhD, Steen Dalby Kristensen, MD, DMSc, Jeffrey L. Anderson, MD, Marco Tubaro, MD, José Luis Lopez Sendon, MD, Christopher B. Granger, MD, Christoph Bode, MD, Kurt Huber, MD, Eric R. Bates, MD, Marco Valgimigli, MD, PhD, Philippe Gabriel Steg, MD, E. Magnus Ohman, MD

Acute coronary syndromes (ACS), either ST-elevation myocardial infarction or non–ST-elevation ACS, are still one of the most common cardiac emergencies with substantial morbidity and mortality. The availability of evidence-based treatments, such as early and intense platelet inhibition and anticoagulation, and timely reperfusion and revascularization, has substantially improved outcomes in patients with ACS. The implementation of streamlined processes of care for patients with ST-elevation myocardial infarction and non–ST-elevation ACS over the last decade including both appropriate tools, especially cardiac troponin, for rapid diagnosis and risk stratification and for decision support, and the widespread availability of modern antithrombotic and interventional treatments, have reduced morbidity and mortality to unprecedented low levels. These changes in the process of care require a synchronized approach, and research using a team-based strategy and effective regional networks has allowed healthcare systems to provide modern treatments for most patients with ACS. There are still areas needing improvement, such as the delivery of care to people in rural areas or with delayed time to treatment.

01 noviembre 2014

AMERICAN HEART JOURNAL. Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrom

Juan Sanchis, MD, Clara Bonanad, MD, Vicente Ruiz, PhD, Julio Fernández, PhD, Sergio García-Blas, MD, Luis Mainar, MD, Silvia Ventura, MD, Enrique Rodríguez-Borja, MD, Francisco J. Chorro, MD, Carlos Hermenegildo, MD, Vicente Bertomeu-González, MD, Eduardo Núñez, MD, Julio Núñez, MD

Background: Geriatric conditions may predict outcomes beyond age and standard risk factors. Our aim was to investigate a wide spectrum of geriatric conditions in survivors after an acute coronary syndrome.

01 septiembre 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Long-term (8 year) outcomes and predictors of major adverse cardiac events after full metal jacket drug-eluting stent implantation

Cheol Whan Lee MD, Jung-Min Ahn MD, Jong-Young Lee MD, Won-Jang Kim MD, Duk-Woo Park MD, Soo-Jin Kang MD, Seung-Whan Lee MD, Young-Hak Kim MD, Seong-Wook Park MD, PhD andSeung-Jung Park MD, PhD*

Objectives: We examined long-term outcomes and predictors of major adverse cardiac events after the full metal jacket (FMJ) stent implantation.

01 octubre 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. MitraClip for severe symptomatic mitral regurgitation in patients at high surgical risk

Femi Philip MD, Ganesh Athappan MD, E. Murat Tuzcu MD, Lars G. Svensson MD, PhD andSamir R. Kapadia MD*

Background: The optimal treatment of patients with severe mitral regurgitation (MR) at high surgical risk (HSR) is unknown. Recently, the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study suggested MitraClip (MC) was a safe and effective treatment option.

01 noviembre 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Balloon aortic valvuloplasty in high risk aortic stenosis patients with left ventricular ejection fractions <20%

Wes R. Pedersen MD1,2,*, Irvin F. Goldenberg MD3, Christopher W. Pedersen BS2, Andrew Lesser BS2, Kevin M. Harris MD1, John R. Lesser MD1, Ross F. Garberich MS2, Jonathan G. Schwartz MD2,4, Emily Shank3 andRobert S. Schwartz MD1,2

Objectives: To determine outcomes following balloon aortic valvuloplasty (BAV) in aortic stenosis (AS) patients with a left ventricular ejection fraction (LVEF) <20%.

01 noviembre 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Single center TAVR experience with a focus on the prevention and management of catastrophic complications

Samir R. Kapadia MD, FSCAI, Lars G. Svensson MD, PhD, Eric Roselli MD, Paul Schoenhagen MD, Zoran Popovic MD, Andrej Alfirevic MD, Benico Barzilai MD, Amar Krishnaswamy MD, William Stewart MD, Anand Mehta MD, Kanhaiya lal Poddar MD, Akhil Parashar MD, Dhruv Modi MD, Alper Ozkan MD, Umesh Khot MD, Bruce W. Lytle MD andE. Murat Tuzcu MD, FSCAI*

Background: Transcatheter aortic valve replacement (TAVR) is an important treatment option for patients with severe symptomatic aortic stenosis (AS) who are inoperable or at high risk for complications with surgical aortic valve replacement. We report here our single-center data on consecutive patients undergoing transfemoral (TF) TAVR since the inception of our program, with a special focus on minimizing and managing complications.